The poor rate of drug discovery for the control of Neglected tropical diseases (NTDs) including schistosomiasis has necessitated effective management of existing drugs by modulating their delivery. Nanotechnology-based colloidal drug carriers have been explored to improve the activity and safety profile of drugs for NTDs including parasitic diseases. In developing new drug delivery systems for schistosomiasis, research efforts have focused mainly on Praziquantel (PZQ) as the sole antischistosomal agent in current clinical practice. Carrier systems of the polymer, inorganic and lipid-based type have been investigated for the delivery of PZQ. However, promising results were obtained using lipid-based delivery systems including liposomes, solid lipid nanoparticles, nanostructured lipid carriers and nanoemulsions. Selection of these lipid carrier systems has been based on the lipophilicity of PZQ, controlled drug release, potential increase in its bioavailability by promoting lymphatic absorption to bypass the extensive first pass effect biodistribution to the host liver and enhancement of PZQ interaction with the worm tegument of a similar phospholipid nature.
